Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03941457Phase 1Unknown

Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer

Role: lead

NCT03940833Phase 1Unknown

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Role: lead

NCT03940820Phase 1Unknown

Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors

Role: lead

NCT03931720Phase 1Unknown

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Role: lead

All 4 trials loaded